Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Can-Fite BioPharma ( (CANF) ) has shared an announcement.
On June 16, 2025, Can-Fite BioPharma announced that it will present progress on its Phase IIa study of Namodenoson for pancreatic cancer at the 2025 BIO International Convention in Boston. The study, led by Prof. Salomon Stemmer, is evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma, showing a favorable safety profile and addressing a critical unmet need for effective treatments. With 50% of the patient cohort already enrolled, Can-Fite aims to engage potential partners to further its clinical pipeline.
The most recent analyst rating on (CANF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
Can-Fite BioPharma’s overall stock score reflects significant financial challenges and a bearish technical outlook. The company’s negative profitability, declining revenues, and reliance on external financing are major concerns. Technical indicators suggest caution, while valuation metrics indicate ongoing losses, affecting investor confidence.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company focused on developing proprietary small molecule drugs for treating cancer and inflammatory diseases. The company targets multi-billion dollar markets with its lead drug candidates, including Piclidenoson for psoriasis and Namodenoson for liver and pancreatic cancers. Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for hepatocellular carcinoma by the FDA.
Average Trading Volume: 282,290
Technical Sentiment Signal: Sell
Current Market Cap: $14.06M
See more insights into CANF stock on TipRanks’ Stock Analysis page.